Bordeaux

France

1,096 total trials 483 recruiting

Filter these 1,096 trials by phase, condition, sponsor and more.

Open in Search →

A study of TG4001 and avelumab cancer immunotherapies in advanced HPV-induced malignancies Ended recruitment

2024-515119-23-00 9 2017-08-29 Phase Ib and Phase II part 1: HPV-16 positive recurrent or metastatic
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination wi … Ended recruitment

2023-509354-58-00 5 2017-07-14 Mantle Cell Lymphoma
Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (PANIRINOX) Ended recruitment

2024-510645-34-00 4 2017-06-28 RAS and B-RAF wild-type metastatic colorectal cancer. RAS and B-RAF mu
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors Ended recruitment

2023-506390-35-00 1 2017-04-19 Patients with Advanced Solid Tumors
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting Ended recruitment

2024-517489-41-00 5 2017-03-27 High-risk stage III colon cancer
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended recruitment

2024-510704-37-00 5 2017-03-22 ER+/HER2- metastatic breast cancer
Comparing two treatment regimen for sinuses tumors and salivary glands: radiotherapy versus chemoradiotherapy Ended recruitment

2024-513972-16-00 5 2017-01-30 - Resected tumors of sinuses or salivary glands - Non-operable tumors
RISK OF INFERTILITY RELATED TO ADJUVANT CHEMOTHERAPY IN YOUNG BREAST CANCER PATIENTS: OOCYTE/EMBRYO CRYOPRESERVATION Ended recruitment

2024-513078-23-00 4 2016-12-02 breast cancer in young women
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended recruitment

2023-510298-33-00 4 2016-11-29 Prostate Cancer
Study of Tumor Alterations Responsive to Targeting Receptor Kinases-2 Ended recruitment

2023-505034-10-00 4 2016-08-01 Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS
PhII Trial of Pembrolizumab in Advanced Solid Tumors Ended recruitment

2022-501253-37-00 4 2016-02-02 (A) Anal Squamous Cell Carcinoma, (B) Biliary Adenocarcinoma (gallblad
An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended recruitment

2023-505246-26-00 5 2016-01-27 High- or very-high risk, localized or locally advanced prostate cancer
RANDOMIZED STUDY COMPARING SENTINEL NODE POLICY TO CURRENT INITIAL STAGING PROTOCOLS IN EARLY STAGE ENDOMETRIAL CARCINOMAS AT INTERMEDIATE A … Ended recruitment

2024-513079-42-00 5 2015-11-19 Intermediate-risk, high risk endometrial cancer
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage … Ended recruitment

2023-509136-25-00 5 2015-07-16 Stage III melanoma (AJCC R0) with histologically confirmed cutaneous m
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations Ended recruitment

2024-514904-14-00 4 2014-10-08 Patients with metastatic or unresectable locally advanced malignancies
A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) Ended recruitment

2024-513455-33-00 4 2014-09-11 Bone sarcoma
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment

2024-511096-15-00 5 2014-08-01 Breast Cancer
A Clinical study to assess the safety and effectiveness of ARN-509 in men with Castration-Resistant Prostate Cancer (prostate cancer not res … Ended recruitment

2023-509221-47-00 5 2014-02-12 Castration-Resistant Prostate Cancer
A large-scale comparative study evaluating an intravenous treatment, cabazitaxel, and radiation therapy to the pelvic lymph nodes in patient … Ended recruitment

2024-517622-25-00 5 2013-12-06 Patients with localized prostate cancer and high-risk features of rela
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy. Ended recruitment

2024-511142-39-00 5 2013-09-06 BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer
A two-year, double-blind, randomized, multicenter, active controlled Core Phase study to evaluate the safety and efficacy of fingolimod admi … Ended recruitment

2023-507556-68-00 5 2013-07-26 Multiple Sclerosis
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free … Ended recruitment

2024-516198-61-00 5 2013-06-05 Patients with high risk of relapse, ER+ and HER2- primary non-metastat
Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco … Ended recruitment

2024-516996-34-00 5 2012-04-12 oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients Ended recruitment

2024-515171-35-00 5 2011-07-06 Prostatic adenocarnicoma with high risk of recurrence

Showing 841–864 of 1,096 trials